95 related articles for article (PubMed ID: 22884159)
21. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).
Druce MR; Kaltsas GA; Fraenkel M; Gross DJ; Grossman AB
Horm Metab Res; 2009 Sep; 41(9):697-702. PubMed ID: 19424940
[TBL] [Abstract][Full Text] [Related]
22. Epithelioid hemangioendothelioma of the kidney treated with sunitinib.
Tolkach Y; Petrov S; Lerut E; Van Poppel H
Onkologie; 2012; 35(6):376-8. PubMed ID: 22722460
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
24. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.
Mannavola D; Coco P; Vannucchi G; Bertuelli R; Carletto M; Casali PG; Beck-Peccoz P; Fugazzola L
J Clin Endocrinol Metab; 2007 Sep; 92(9):3531-4. PubMed ID: 17595247
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinase inhibitor induced pancreatitis.
Sevin A; Chen A; Atkinson B
J Oncol Pharm Pract; 2013 Sep; 19(3):257-60. PubMed ID: 23034406
[TBL] [Abstract][Full Text] [Related]
27. The potential of sunitinib as a therapy in ovarian cancer.
Leone Roberti Maggiore U; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Investig Drugs; 2013 Dec; 22(12):1671-86. PubMed ID: 24070205
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
29. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Lin CI; Whang EE; Lorch JH; Ruan DT
Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
Toledo R; Jimenez C
F1000Res; 2018; 7():. PubMed ID: 30109021
[TBL] [Abstract][Full Text] [Related]
31. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017).
Musser ML; Taikowski KL; Johannes CM; Bergman PJ
BMC Vet Res; 2018 Sep; 14(1):272. PubMed ID: 30176869
[TBL] [Abstract][Full Text] [Related]
32. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Nishikawa T; Nakano M; Tanabe K
Jpn J Clin Oncol; 2010 Dec; 40(12):1173-9. PubMed ID: 20696817
[TBL] [Abstract][Full Text] [Related]
33. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
34. Long-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcoma.
Porzio R; Bella MA; Rossi G; Ardizzoni A
Anticancer Res; 2013 Mar; 33(3):1061-3. PubMed ID: 23482782
[TBL] [Abstract][Full Text] [Related]
35. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
36. Streptozotocin therapy for malignant pheochromocytoma.
Gross DJ; Schlank E; Ipp E
Arch Intern Med; 1985 Feb; 145(2):367-8. PubMed ID: 3156568
[No Abstract] [Full Text] [Related]
37. Response to sunitinib malate in advanced alveolar soft part sarcoma.
Stacchiotti S; Tamborini E; Marrari A; Brich S; Rota SA; Orsenigo M; Crippa F; Morosi C; Gronchi A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2009 Feb; 15(3):1096-104. PubMed ID: 19188185
[TBL] [Abstract][Full Text] [Related]
38. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
Paule B; Brion N
Anticancer Res; 2011 Oct; 31(10):3507-10. PubMed ID: 21965770
[TBL] [Abstract][Full Text] [Related]
39. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
40. Suppressing effects of sunitinib on allergic rhinitis: previously undefined side effects with therapeutic potential.
Eechoute K; van Zonneveld M; van Daele PL; van Wijk RG; Mathijssen RH
J Clin Pharmacol; 2011 Nov; 51(11):1592-5. PubMed ID: 21189307
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
